Warning for Blood Clot Risk Added to Drospirenone OCPs

April 11, 2012

The U.S. Food and Drug Administration (FDA) has completed its review of recent observational (epidemiologic) studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills. Drospirenone is a synthetic version of the female hormone, progesterone, also referred to as a progestin. Based on this review, FDA has concluded that drospirenone-containing birth control pills may be associated with a higher risk for blood clots than other progestin-containing pills.

Facebook Comments

Register

We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free